GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » 14-Day RSI

Imagion Biosystems (ASX:IBX) 14-Day RSI : 78.55 (As of Jun. 23, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-23), Imagion Biosystems's 14-Day RSI is 78.55.

The industry rank for Imagion Biosystems's 14-Day RSI or its related term are showing as below:

ASX:IBX's 14-Day RSI is ranked worse than
97.93% of 241 companies
in the Medical Diagnostics & Research industry
Industry Median: 44.62 vs ASX:IBX: 78.55

Competitive Comparison of Imagion Biosystems's 14-Day RSI

For the Diagnostics & Research subindustry, Imagion Biosystems's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imagion Biosystems's 14-Day RSI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's 14-Day RSI falls into.



Imagion Biosystems  (ASX:IBX) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Imagion Biosystems  (ASX:IBX) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Imagion Biosystems 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Imagion Biosystems (ASX:IBX) Business Description

Traded in Other Exchanges
N/A
Address
5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems (ASX:IBX) Headlines

No Headlines